Thursday 11 June 2020

The Brewery, London EC1


2014 News

2014 Showreel

2014 press releases and articles

Wall Street Journal coverage
Cardio3 BioSciences Nominated for the European Mediscience Awards 2014

MarketWatch coverage
Ablynx wins Transaction of the year award at the 2014 European Mediscience Awards

Cambridge Network coverage
Horizon Discovery wins European Mediscience's Emerging Star Award 2014

Burton Mail
Boss of drugs com

2014 Tweets

Our social media campaign reached over 395,000 people. A selection of tweets are included below:

Pleased to see @JohncFierce of @FierceBiotech has won "Commentator of the Year" from @EuroMed_Awards. #Congrats

ACRO @ACROhealth

Here’s our CEO Peter George accepting his Chief Executive of the Year award at @EuroMed_Awards

Clinigen Group @Clinigen

Congratulations to @AblynxNV for winning the transaction of the year award at @EuroMed_Awards! #pharma

ThePharmaLetter @ThePharmaLetter

Lovely to meet @louiseminchin at the @EuroMed_Awards last night! Good luck with the triathlons!

Claire @Claire_PHD

"@AblynxABLX: #Ablynx wins Transaction of the Year at this year's @EuroMed_Awards" #BelgianBiotech

Gorryt De Ruyck @Gorryt_De_Ruyck

Congrats! MT @AblynxABLX: #Ablynx wins Transaction of the Year at 2014 European Mediscience Awards @EuroMed_Awards

VIB @VIBLifeSciences

Interviews with members of our Voting Panel

The members of the Voting Panel discussed the merits of each nomination at a meeting held on Tuesday 20 May 2014. After considerable discussion and debate, each panel member confidentially allocated points to each company or individual, producing a short list and ultimately a winner in each of the nine categories.

Some interviews discussing key industry insights were conducted on the day of the meeting with the panel members below and can be viewed by pressing play.

Victoria Darbyshire, JP Morgan

Geraldine O'Keeffe, Life Sciences Partners

Nick Rodgers, Oxford BioMedica

Dr Ivo Staijen, CFA, HBM Partners AG

Elise Wang, Deerfield

Industry talk


Our headline sponsor, Kempen & Co recently held a one day Healthcare/Life Sciences conference in Amsterdam. Many key industry figures attended and Ford Sinclair took the opportunity to speak to a couple of European Mediscience Awards supporters to find out what key R&D developments there have been.


Jan G.J. van de Winkel, PhD

President and CEO, Genmab A/S

"In terms of industry developments, networking and strategic partnering become increasingly important in the innovation ecosystem. Knowledge sharing and collaboration between Pharma, Biotechnology and Academic players is key to create innovative therapeutic formats and differentiated drugs. The goal is to create and develop breakthrough drugs that profoundly improve the quality of life for patients and their families."


Elizabeth Goodwin

Head of Corporate Communications and Investor Relations, Galapagos

"Regarding the key R&D development in biotech, we've seen an increase in funding available in the US – just look at all the IPOs and funding rounds there the last year. It's been great to see, as raising funding for pipelines is always a key issue for the industry. We've also seen that European biotech is delivering in the clinic, which works hand in hand with funding and generates lots of optimism."